CAR T cell therapy leads to 10-year remissions in B-cell lymphoma patients

by Perelman School of Medicine at the University of Pennsylvania

edited by Sadie Harley, reviewed by Robert Egan

Sadie Harley

Scientific Editor

Meet our editorial team
Behind our editorial process

Robert Egan

Senior Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

The GIST Add as preferred source

After a median follow-up of 10 years, more than one-third of patients with large B-cell lymphoma and nearly half of patients with follicular lymphoma who received a single infusion of tisagenlecleucel—the CAR T-cell therapy developed by Carl June, MD, that would go on to become the first such treatment approved by the FDA—were still alive without a lymphoma relapse, according to long-term follow-up data published in New England Journal of Medicine by researchers from the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania.

In the analysis of 38 patients from a Phase II clinical trial (including 24 patients with large B-cell lymphoma and 14 with follicular lymphoma) conducted at Penn Medicine's Abramson Cancer Center, no patients experienced a relapse after 5.4 years, and most relapses occurred within the first year after CAR T-cell infusion, supporting the hypothesis that patients who experience a long-term response to CAR T-cell therapy may be cured.

"As oncologists, we use the word 'cure' with great care, but I am increasingly confident that CAR T-cell therapy has the potential to cure a meaningful number of patients with B-cell lymphomas," said senior author Stephen J. Schuster, MD, the Robert and Margarita Louis-Dreyfus Professor in Chronic Lymphocytic Leukemia and Lymphoma Clinical Care and Research and director of Penn's Lymphoma Program.

"At the same time, our work is far from done. This therapy does not yet work for everyone, and we are committed to understanding why so we can continue to improve the next generation of CAR Ts."

Patients with a longer response appeared to have higher levels of CAR T cells in their blood over the first two years after treatment, a finding consistent with reports of durable response to CAR T-cell therapy in other cancer types. The persistence of CAR T cells also seemed to be more important than the early peak expansion of CAR T cells.

Long-term safety makes a case for earlier CAR T therapy

The clinical trial enrolled patients with relapsed/refractory disease, meaning their cancer had returned after and/or had stopped responding to other treatments.

At study enrollment, patients had received a median of four previous therapies, including chemotherapy, and for some, autologous (self) stem cell transplant. Many of these therapies also carry their own long-term risks, and it's difficult to attribute the specific cause of long-term adverse events.

Two of the 38 patients had ongoing grade 2 or 3 neutropenia (low white blood cell counts), and there were no cases of ongoing anemia or thrombocytopenia. Importantly, more than half of all patients with a long-term response recovered normal B cells, an important part of the immune system, without recurrence of their B-cell lymphoma.

No patients in the study had a secondary case of CAR T cell-related lymphoma, as assessed by the investigator. Nine patients did develop a second primary cancer, including acute myeloid leukemia (in three patients, all with characteristic prior therapy-associated genetic mutations), prostate cancer (two patients), lung cancer (two patients, both with a smoking history), melanoma (one patient), and a form of T-cell lymphoma that affects the skin (one patient).

The overall 10-year incidence of a second primary cancer was higher in the study population than in comparable U.S. SEER data, though it is consistent with other reports from patients with lymphoma treated with chemotherapy and autologous transplant.

"We're encouraged by the long-term remissions of these patients over the past decade," said lead author Marco Ruella, MD, an associate professor of Hematology-Oncology and scientific director of the Lymphoma Program. "Moving CAR T-cell therapy into earlier lines of treatment—before patients experience the cumulative effects of chemotherapy—may be key to extending its curative potential."

The research team currently has multiple projects in progress evaluating different strategies to improve the effectiveness of CAR T-cell therapy, including evaluating whether the lymphodepleting chemotherapy that patients currently receive before CAR T-cell therapy is necessary, as it is for stem cell (bone marrow) transplants.

Publication details

Marco Ruella et al, Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas, New England Journal of Medicine (2026). DOI: 10.1056/nejmoa2518035

Journal information: New England Journal of Medicine

Key medical concepts

tisagenlecleucelLymphoma, Large B-Cell, DiffuseLymphoma, FollicularAcute Myeloid Leukemia

Clinical categories

Oncology Provided by Perelman School of Medicine at the University of Pennsylvania Who's behind this story?

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: CAR T cell therapy leads to 10-year remissions in B-cell lymphoma patients (2026, June 25) retrieved 25 June 2026 from https://medicalxpress.com/news/2026-06-car-cell-therapy-year-remissions.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.